US 11,969,435 B2
Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
Joseph K. Belanoff, Menlo Park, CA (US)
Assigned to Corcept Therapeutics, Inc., Menlo Park, CA (US)
Filed by Corcept Therapeutics, Inc., Menlo Park, CA (US)
Filed on Dec. 7, 2021, as Appl. No. 17/544,859.
Application 17/544,859 is a continuation of application No. 16/482,656, abandoned, previously published as PCT/US2018/020336, filed on Feb. 28, 2018.
Claims priority of provisional application 62/465,772, filed on Mar. 1, 2017.
Claims priority of provisional application 62/466,867, filed on Mar. 3, 2017.
Prior Publication US 2022/0088036 A1, Mar. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/575 (2006.01); A61K 9/00 (2006.01); A61K 31/496 (2006.01); A61K 31/7048 (2006.01); A61K 45/06 (2006.01); A61P 3/10 (2006.01)
CPC A61K 31/575 (2013.01) [A61K 9/0056 (2013.01); A61K 31/496 (2013.01); A61K 31/7048 (2013.01); A61K 45/06 (2013.01); A61P 3/10 (2018.01)] 17 Claims
 
1. A method of treating hyperglycemia secondary to hypercortisolism in a patient with Cushing's syndrome, said patient taking an original once-daily (OD) oral dose of 1200 milligrams per day (mg/day) of mifepristone, comprising reducing said original OD oral mifepristone dose of 1200 mg/day to an adjusted OD oral mifepristone dose of 900 mg/day wherein the patient is receiving concomitant administration of a strong CYP3A inhibitor selected from the group consisting of ketoconazole, itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, boceprevir, clarithromycin, conivaptan, lopinavir, posaconazole, saquinavir, telaprevir, cobicistat, troleandomycin, tipranavir, paritaprevir and voriconazole.